<DOC>
	<DOC>NCT02369159</DOC>
	<brief_summary>This study will evaluate the safety, pharmacokinetics and effectiveness of a single dose of IV peramivir compared to a standard 5 day course of oral oseltamivir in the treatment of pediatric subjects with acute uncomplicated influenza. Two thirds of the participants will receive peramivir, while one third will receive oseltamivir.</brief_summary>
	<brief_title>Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza</brief_title>
	<detailed_description />
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Oseltamivir</mesh_term>
	<mesh_term>Peramivir</mesh_term>
	<criteria>Key 1. Clinical signs and symptoms consistent with acute influenza infection consisting of an oral temperature ≥ 100°F (37.8°C) or rectal temperature ≥ 101.3ºF (≥ 38.5ºC) with at least one respiratory symptom (cough or rhinitis) OR Positive influenza determined by PCR or Rapid Antigen Test 2. Influenza symptom onset &lt; 48 hours Key 1. Pregnant or breastfeeding females 2. Development of symptoms while hospitalized 3. Presence of a chronic disease or illness that may indicate increased risk for influenzarelated complications 4. Presence of immunocompromised status</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>